DOI
https://doi.org/10.18849/ve.v8i4.673Abstract
PICO Question
In dogs with chronic enteropathy (idiopathic inflammatory bowel disease) is budesonide more effective than prednisolone or prednisone in resolving clinical signs or improving the canine inflammatory bowel disease (IBD) activity index (CIBDAI) or the canine chronic enteropathy clinical activity index (CCECAI)?
Clinical bottom line
Category of research
Treatment.
Number and type of study designs reviewed
One double-blinded randomised control trial.
Strength of evidence
Moderate.
Outcomes reported
The outcome of this study identified that no significant differences in remission rates (> 75% decrease in CIBDAI scores) were observed between the prednisone and budesonide groups. Frequency of adverse effects were also similar between the two groups.
Conclusion
A single study with moderate power of evidence alongside some significant limitations, particularly population size, cannot be used as the sole provider of an answer to the PICO question. As such, further studies with greater power would be required before a definitive assessment of comparative treatment efficacy can be made.
How to apply this evidence in practice
The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
References
Becker, D.E. (2013). Basic and Clinical Pharmacology of Glucocorticosteroids. Anaesthesia Progress. 60 (1), 25–32. DOI: https://doi.org/10.2344%2F0003-3006-60.1.25
Dye, T.L., Diehl, K.J., Wheeler, S.L. & Westfall, D.S. (2013). Randomized, Controlled Trial of Budesonide and Prednisone for the Treatment of Idiopathic Inflammatory Bowel Disease in Dogs. Journal of Veterinary Internal Medicine. 27, 1385–1391. DOI: https://doi.org/10.1111/jvim.12195
Pietra, M., Fracassi, F., Diana, A., Gazzotti, T., Bettini, G., Peli, A., Morini, M., Pagliuca, G. & Roncada, P. (2013). Plasma concentrations and therapeutic effects of budesonide in dogs with inflammatory bowel disease. American Journal of Veterinary Research. 74 (1), 78–83. DOI: https://doi.org/10.2460/ajvr.74.1.78
Tumulty, J.W., Broussard, J.D., Steiner, J.M., Peterson, M.E. & Williams, D.A. (2004). Clinical Effects of Short-Term Oral Budesonide on the Hypothalamic-Pituitary-Adrenal Axis in Dogs With Inflammatory Bowel Disease. Journal of the American Animal Hospital Association. 40 (2), 120–123. DOI: https://doi.org/10.5326/0400120
Stroup, S.T., Behrend, E.N., Kemppainen, R.J. & Smith-Carr, S. (2006). Effects of oral administration of controlled-ileal-release budesonide and assessment of pituitary-adrenocortical axis suppression in clinically normal dogs. American Journal of Veterinary Research. 67 (7), 1173–1178. DOI: https://doi.org/10.2460/ajvr.67.7.1173
License
Copyright (c) 2023 Victoria Alice Coates
This work is licensed under a Creative Commons Attribution 4.0 International License.
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.
